
-
DiaMedica Therapeutics NasdaqCM:DMAC DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Location: 301 Carlson Parkway, Minneapolis, MN, 55305, United States | Website: https://www.diamedica.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
143.7M
Cash
36.32M
Avg Qtr Burn
-5.643M
Short % of Float
3.55%
Insider Ownership
15.65%
Institutional Own.
36.00%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DM199 (KLK1 protein) Details Heart disease, Ischemic stroke | Phase 2/3 Data readout | |
Phase 2 Data readout | ||
DM199 (KLK1 protein) Details Chronic inflammatory disorder, Inflammatory disease, Kidney disease, IgA nephropathy, Chronic kidney disease | Phase 2 Update |